MET and non-small cell lung carcinoma: Overall, we identified biomarkers associated with osimertinib resistance, such as c-Met, which can enhance our understanding of the mechanisms underlying osimertinib resistance and contribute to the development of more effective strategies for overcoming resistance in NSCLC patients.